Cover Image
市場調查報告書

心肺自我輸血系統的全球市場:2016∼2020年

Global Cardiopulmonary Autotransfusion Systems Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 361560
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
心肺自我輸血系統的全球市場:2016∼2020年 Global Cardiopulmonary Autotransfusion Systems Market 2016-2020
出版日期: 2016年06月17日 內容資訊: 英文 65 Pages
簡介

自我輸血包括手術前的集血,在心血管手術中輸血,為了將失血抑制在最小限度進行的自我輸血系統。全球心肺自我輸血系統市場,預計2016∼2020年,以年複合成長率1.91%擴大。

本報告提供全球心肺自我輸血系統市場現狀與2020年的預測,市場規模與銷售趨勢,彙整主要供應商的競爭環境與簡介。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 醫療設備分類

第6章 成本分析

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各終端用戶市場區隔

  • 醫院
  • ASC

第9章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 推動市場的要素

  • 心血管手術的增加
  • 同類輸血的併發症
  • 自我輸血技術的進步

第11章 促進要素的影響

第12章 市場課題

  • 自我輸血技術的限制
  • 同類輸血的使用
  • 嚴格的相關法規和醫療政策

第13章 促進要素與課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式

第16章 主要供應商分析

  • Advancis Surgical
  • Fresenius Kabi
  • Haemonetics
  • LivaNova
  • Medtronic
  • Terumo Corporation
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

目錄
Product Code: IRTNTR9485

About the Cardiopulmonary Autotransfusion Systems Market

Autotransfusion involves the collection of blood before surgeries and its transfusion during cardiac operations. This procedure is processed in autotransfusion systems that help minimize blood loss by collecting and filtering the RBCs, and reinfusing the blood into an individual.

Autotransfusion is an autologous technology involving the retransfusion of a person's own blood, which increases the need for traditional centrifuge devices for separating the RBCs from the blood. Advances in technology have led companies to integrate ultrafiltration technique for blood collection. For instance, Advancis Surgical's ultrafiltration-based HemoSep system can improve patient recovery time by filtering inflammatory molecules, preserving normal clotting function, and maintaining platelet populations.

Technavio's analysts forecast the global cardiopulmonary autotransfusion systems to grow at a CAGR of 1.91% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cardiopulmonary autotransfusion systems for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of cardiopulmonary autotransfusion systems globally. These systems help reduce the risk of infections that can occur due to the use of allogenic blood.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Cardiopulmonary Autotransfusion Systems Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Advancis Surgical
  • Fresenius Kabi
  • Haemonetics
  • LivaNova
  • Medtronic
  • Terumo

Other Prominent Vendors

  • Atrium Medical
  • Global Blood Resources
  • Redax
  • Sarstedt
  • Stryker

Market driver

  • Rise in cardiac surgeries
  • For a full, detailed list, view our report

Market challenge

  • Limitations of autotransfusion technology
  • For a full, detailed list, view our report

Market trend

  • Development of ultrafiltration systems
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Cardiopulmonary diseases: An overview
  • Cardiopulmonary autotransfusion systems: An overview
  • Role of autotransfusion in cardiac surgeries
  • Cardiopulmonary autotransfusion process

PART 05: Classification of medical devices

  • Classification of medical devices

PART 06: Cost analysis

  • Cost analysis of cardiopulmonary autotransfusion systems

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by end-user

  • Hospitals
  • ASCs

PART 09: Geographical segmentation

  • Cardiopulmonary autotransfusion systems market in Americas
  • Cardiopulmonary autotransfusion systems market in EMEA
  • Cardiopulmonary autotransfusion systems market in APAC

PART 10: Market drivers

  • Rise in cardiac surgeries
  • Complications of allogenic blood transfusion
  • Advances in autotransfusion technology

PART 11: Impact of drivers

PART 12: Market challenges

  • Limitations of autotransfusion technology
  • Use of allogenic blood transfusion
  • Stringent regulatory framework and medical policies

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Development of ultrafiltration systems
  • Significant opportunities in emerging countries
  • Public awareness

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Major vendors

  • Advancis Surgical
  • Fresenius Kabi
  • Haemonetics
  • LivaNova
  • Medtronic
  • Terumo
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of cardiopulmonary diseases
  • Exhibit 03: Peri-operative period and its different stages
  • Exhibit 04: History of autotransfusion
  • Exhibit 05: Autotransfusion systems for other surgeries
  • Exhibit 06: Process of autotransfusion
  • Exhibit 07: Components of cardiopulmonary autotransfusion system
  • Exhibit 08: Cost analysis of cardiopulmonary autotransfusion
  • Exhibit 09: Cost breakdown of CABG surgery and cardiopulmonary autotransfusion 2015
  • Exhibit 10: Global cardiopulmonary autotransfusion systems market 2015-2020 ($ millions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global cardiopulmonary autotransfusion systems market segmentation by end-user 2015
  • Exhibit 13: Global cardiopulmonary autotransfusion systems market segmentation by geography 2015
  • Exhibit 14: Global cardiopulmonary autotransfusion systems market segmentation by geography 2020
  • Exhibit 15: Global cardiopulmonary autotransfusion systems market segmentation by geography 2015-2020
  • Exhibit 16: Global cardiopulmonary autotransfusion systems market segmentation by geography 2015-2020 ($ millions)
  • Exhibit 17: Cardiopulmonary autotransfusion systems market in Americas 2015-2020 ($ millions)
  • Exhibit 18: Comparison of US healthcare system: Before and after reforms
  • Exhibit 19: Implements amended in ACA
  • Exhibit 20: Number of coronary bypass surgeries per 100,000 people in Europe 2013
  • Exhibit 21: Cardiopulmonary autotransfusion systems market in EMEA 2015-2020 ($ millions)
  • Exhibit 22: Cardiopulmonary autotransfusion systems market in APAC 2015-2020 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Advancis Surgical: Key takeaways
  • Exhibit 26: Fresenius Kabi: Key products
  • Exhibit 27: Fresenius Kabi: Key takeaways
  • Exhibit 28: Haemonetics: Product segmentation by revenue FY2016
  • Exhibit 29: Haemonetics: Product segmentation by revenue 2015 and FY2016 ($ millions)
  • Exhibit 30: Haemonetics: Key takeaways
  • Exhibit 31: LivaNova: Key products
  • Exhibit 32: LivaNova: Revenue of cardiac surgery segment by geographical segmentation 2015
  • Exhibit 33: LivaNova: Key takeaways
  • Exhibit 34: Medtronic: Key product
  • Exhibit 35: Medtronic: Key takeaways
  • Exhibit 36: Terumo: Key product
  • Exhibit 37: Terumo: Key takeaways
Back to Top